Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leon Aarons

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 2, 2010
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactionsEleanor J Guest, Leon Aarons, J Brian Houston, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 yearsMaria Pitsiu, Ziad Hussein, Oneeb Majid, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC studyZiad Hussein, Maria Pitsiu, Oneeb Majid, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2020
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluationAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
Biopharmaceutics & Drug Disposition|March 14, 2002
Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or anginaSuneel Gupta, Nishit B Modi, Gayatri Sathyan, et al.
Journal of Clinical Pharmacology|October 15, 2013
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?Farzaneh Salem, Kayode Ogungbenro, Pavan Vajjah, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 19, 2024
Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancerDavid Hodson, Hitesh Mistry, James Yates, et al.
Pharmaceutical Research|December 3, 2014
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK ApproachNikolaos Tsamandouras, Gemma Dickinson, Yingying Guo, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, James G Wright, et al.
Pharmaceutical Research|September 28, 2013
The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal dataAndrés Olivares-Morales, Oliver J D Hatley, David Turner, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 2, 2010
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactionsEleanor J Guest, Leon Aarons, J Brian Houston, et al.
British Journal of Clinical Pharmacology|March 18, 2004
Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 yearsMaria Pitsiu, Ziad Hussein, Oneeb Majid, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC studyZiad Hussein, Maria Pitsiu, Oneeb Majid, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2020
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluationAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
Biopharmaceutics & Drug Disposition|March 14, 2002
Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or anginaSuneel Gupta, Nishit B Modi, Gayatri Sathyan, et al.
Journal of Clinical Pharmacology|October 15, 2013
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?Farzaneh Salem, Kayode Ogungbenro, Pavan Vajjah, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 19, 2024
Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancerDavid Hodson, Hitesh Mistry, James Yates, et al.
Pharmaceutical Research|December 3, 2014
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK ApproachNikolaos Tsamandouras, Gemma Dickinson, Yingying Guo, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, James G Wright, et al.
Pharmaceutical Research|September 28, 2013
The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal dataAndrés Olivares-Morales, Oliver J D Hatley, David Turner, et al.
Pageof 13